Oncology ·
First-Line Strategies for ERBB2-Positive Metastatic Breast Cancer Evolve
This review discusses changing first-line and maintenance strategies for ERBB2-positive metastatic breast cancer. It highlights results from DESTINY-Breast09 and other trials, while noting that optimal treatment selection, sequencing, and duration remain uncertain.
- DESTINY-Breast09 supports trastuzumab deruxtecan plus pertuzumab.
- Maintenance approaches are expanding, including CDK4/6 inhibitor combinations.
- Optimal sequencing and treatment duration remain uncertain.
- HER2DX and circulating tumor DNA remain investigational.
Treatment for ERBB2-positive metastatic breast cancer has traditionally started with a taxane plus trastuzumab and pertuzumab, followed by maintenance anti-ERBB2 therapy, with endocrine therapy considered according to hormone-receptor status. This review surveys newer approaches that are challenging that induction-maintenance model.
The authors report that DESTINY-Breast09 (NCT04784715) found longer progression-free survival with trastuzumab deruxtecan plus pertuzumab, supporting recent US Food and Drug Administration approval. Maintenance options have also expanded: PATINA studied endocrine therapy and a CDK4/6 inhibitor in hormone receptor–positive disease, while HER2CLIMB-05 evaluated a three-drug anti-ERBB2 maintenance strategy. The review also describes investigational biomarker approaches, including HER2DX and circulating tumor DNA, and chemotherapy-free strategies such as SAPPHO.
The authors conclude that treatment is moving toward more individualized choices that balance efficacy, toxicity, and patient preferences. They emphasize unresolved questions about chemotherapy’s role, antibody-drug conjugate treatment duration, sequencing, and dual ERBB2 blockade. The supplied abstract does not provide trial sample sizes or numerical efficacy and safety results; biomarker-guided strategies remain investigational.
In practice
For clinicians treating ERBB2-positive metastatic breast cancer, the review describes trastuzumab deruxtecan plus pertuzumab as a newly FDA-approved first-line option supported by superior progression-free survival in DESTINY-Breast09. It also outlines expanded maintenance strategies, including endocrine therapy with a CDK4/6 inhibitor in hormone receptor–positive disease. The abstract provides no effect sizes, sample sizes, or comparative safety details, and emphasizes that optimal selection, sequencing, and duration remain unsettled; biomarker-guided approaches are not yet routine.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
JAMA Oncology: Evolving First-Line Treatment Strategies in ERBB2 -Positive Metastatic Breast Cancer ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.